A study of immunologic parameters of lung cancer (LC) patients receiving immunotherapy as factors that could predict their effect
Latest Information Update: 09 Jul 2021
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 09 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.